Pancreatic Cancer Research

ResearcherArmy Medical UniversityNo recent work listed

Yichen Tang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1032-0636; OpenAlex author ID A5101948389. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers

Papers 7

  1. Short-Term Outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.5210↗
  2. Clinical and genetic characteristics in pancreatic cancer from Chinese patients revealed by whole exome sequencing. Co-author DOI 10.3389/fonc.2023.1167144↗
  3. Actin gamma 1 is a critical regulator of pancreatic ductal adenocarcinoma. Co-author DOI 10.4103/sjg.sjg_356_21↗
  4. Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinoma: A retrospective study. Co-author DOI 10.4251/wjgo.v14.i9.1785↗
  5. Asiaticoside inhibits epithelial-mesenchymal transition and stem cell-like properties of pancreatic cancer PANC-1 cells by blocking the activation of p65 and p… Co-author DOI 10.21037/jgo-20-533↗
  6. miR-15a inhibits cell proliferation and epithelial to mesenchymal transition in pancreatic ductal adenocarcinoma by down-regulating Bmi-1 expression. Co-author DOI 10.1016/j.canlet.2013.10.009↗
  7. Increased intratumoral interleukin 22 levels and frequencies of interleukin 22-producing CD4+ T cells correlate with pancreatic cancer progression. First author DOI 10.1097/mpa.0000000000000055↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaobing Huang · 4 shared papers, 2021–2023 · strength 0.71
  2. Lu Zheng · 2 shared papers, 2021–2023 · strength 0.32
  3. Yonggang He · 2 shared papers, 2021–2022 · strength 0.32
  4. Jing Li · 1 shared paper, 2022 · strength 0.22
  5. Nan You · 1 shared paper, 2023 · strength 0.17
  6. Yonggang He · 1 shared paper, 2023 · strength 0.17
  7. Lu Zheng · 1 shared paper, 2022 · strength 0.16
  8. Zhenxiong Zhang · 1 shared paper, 2023 · strength 0.12
  9. Hongqin Ma · 1 shared paper, 2023 · strength 0.12
  10. Shutao Pan · 1 shared paper, 2023 · strength 0.12
  11. Xuemin Chen · 1 shared paper, 2023 · strength 0.12
  12. Jingdong Li · 1 shared paper, 2023 · strength 0.12
  13. Min Wang · 1 shared paper, 2023 · strength 0.12
  14. Yahui Liu · 1 shared paper, 2023 · strength 0.12
  15. Pei Lu · 1 shared paper, 2023 · strength 0.12
  16. Zheng Li · 1 shared paper, 2023 · strength 0.12
  17. Jun Liu · 1 shared paper, 2023 · strength 0.12
  18. Xianjun Yu · 1 shared paper, 2023 · strength 0.12
  19. Chen Liu · 1 shared paper, 2023 · strength 0.12
  20. Rong Liu · 1 shared paper, 2023 · strength 0.12
  21. Xiaowu Xu · 1 shared paper, 2023 · strength 0.12
  22. Renyi Qin · 1 shared paper, 2023 · strength 0.12
  23. Shunrong Ji · 1 shared paper, 2023 · strength 0.12
  24. Xuejun Xu · 2 shared papers, 2014 · strength 0.09
  25. Shixiang Guo · 2 shared papers, 2014 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.